Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Feb;279(2):255-7.
doi: 10.1007/s00404-008-0698-0. Epub 2008 Jun 4.

A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole

Affiliations
Case Reports

A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole

Kaei Nasu et al. Arch Gynecol Obstet. 2009 Feb.

Abstract

Background: Benign metastasizing leiomyoma (BML) is a rare disease most often located in the lungs of women with a history of surgery for benign leiomyoma of the uterus. Optimum therapy for BML, has not been established. We report here an additional case of BML in the lung that was successfully treated with surgical castration followed by hormonal therapy with anastrozole, an aromatase inhibitor.

Case: A 46-year-old primigravid Japanese woman was admitted to our hospital for investigation of multiple pulmonary nodules found on a routine chest X-ray. At the age of 36, she had undergone myomectomy for uterine myomas. Upon gynecological examination, her uterus, was enlarged to the size of a child's head. Abdominal total hysterectomy, bilateral salpingo-oophorectomy, and thoracoscopic biopsy of pulmonary nodules were performed. Histologically, the lung nodules were diagnosed as BML. Subsequently oral anastrozole was started. The patient is alive and the size of the pulmonary nodules was stable, 15 months following the surgery.

Conclusion: In addition to castration by bilateral oophorectomy or gonadotropin-releasing hormone agonist, the use of aromatase inhibitor is one of the treatment options for the further suppression of peripheral estrogen production in these patients.

PubMed Disclaimer

Publication types

LinkOut - more resources